Apraclonidine

CHEMBL647 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
245.1 g/mol
LogP
1.3
Phase
4

An alpha-2 adrenergic agonist used as eye drops to lower intraocular pressure in glaucoma by reducing the production of aqueous humor inside the eye. It is particularly useful for controlling pressure spikes following laser eye procedures.

分子量

245.1100 g/mol

LogP

1.30

TPSA

62.40 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1

InChI

InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)

Molecular Formula

C9H10Cl2N4

HBD / HBA

3 / 2

回転可能結合数

2

重原子数

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An alpha-2 adrenergic agonist used as eye drops to lower intraocular pressure in glaucoma by reducing the production of aqueous humor inside the eye. It is particularly useful for controlling pressure spikes following laser eye procedures.

Yes, Apraclonidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL647. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2216. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.